1887
No metrics data to plot.
The attempt to load metrics for this article has failed.
The attempt to plot a graph for these metrics has failed.

Role of the Health Department in Tuberculosis Prevention and Control—Legal and Public Health Considerations

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.
  • HTML
    166.22 Kb
  • PDF
    1.03 MB
  • XML
    135.76 Kb
  • Authors: Carla Jeffries1, Phil Lobue2, Terence Chorba3, Beverly Metchock4, Ijaz Kashef5
  • Editor: David Schlossberg6
  • VIEW AFFILIATIONS HIDE AFFILIATIONS
    Affiliations: 1: Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA 30333; 2: Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA 30333; 3: Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA 30333; 4: Division of Tuberculosis Elimination, Centers for Disease Control and Prevention, Atlanta, GA 30333; 5: Division of Global Health Protection, Centers for Disease Control and Prevention, Atlanta, GA 30333; 6: Philadelphia Health Department, Philadelphia, PA
    • Source: microbiolspec March 2017 vol. 5 no. 2 doi:10.1128/microbiolspec.TNMI7-0034-2016
  • Received 05 December 2016 Accepted 09 December 2016 Published 03 March 2017
  • Carla Jeffries, [email protected]
image of Role of the Health Department in Tuberculosis Prevention and Control—Legal and Public Health Considerations
    Preview this microbiology spectrum article:
    Preview Magnify
    Zoom in
    Zoomout

    Role of the Health Department in Tuberculosis Prevention and Control—Legal and Public Health Considerations, Page 1 of 2

    | /docserver/preview/fulltext/microbiolspec/5/2/TNMI7-0034-2016-1.gif /docserver/preview/fulltext/microbiolspec/5/2/TNMI7-0034-2016-2.gif

  • Abstract:

    Because tuberculosis is caused by an infectious organism that is spread from person to person through the air, public health measures are essential to control the disease. There are three priority strategies for tuberculosis prevention and control in the United States: (i) identifying and treating persons who have tuberculosis disease; (ii) finding persons exposed to infectious tuberculosis patients, evaluating them for infection and disease, and providing subsequent treatment, if appropriate; and (iii) testing populations at high risk for latent tuberculosis infection (LTBI) and treating those persons who are infected to prevent progression to disease. These strategies for prevention and control of tuberculosis are discussed in a framework containing the following important topics: historical and epidemiological context of tuberculosis control, organization of public health tuberculosis control programs, legal basis for public health authority, conducting overall planning and development of policy, identifying persons who have clinically active tuberculosis, evaluation of immigrants, managing persons who have or who are suspected of having disease, medical consultation, interjurisdictional referrals, identifying and managing persons infected with , providing laboratory and diagnostic services, collecting and analyzing data, and providing training and education. This chapter describes the role of the health department in the context of these components. This discussion is primarily applicable to tuberculosis prevention and control programs in the United States.

  • Citation: Jeffries C, Lobue P, Chorba T, Metchock B, Kashef I. 2017. Role of the Health Department in Tuberculosis Prevention and Control—Legal and Public Health Considerations. Microbiol Spectrum 5(2):TNMI7-0034-2016. doi:10.1128/microbiolspec.TNMI7-0034-2016.

References

1. Advisory Council for the Elimination of Tuberculosis. 1995. Essential components of a tuberculosis prevention and control program. Recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR Recommemd Rep 44(RR-11) :1–16. [PubMed]
2. Lerner BH. 1999. Catching patients: tuberculosis and detention in the 1990s. Chest 115:236–241. [PubMed]
3. Gasner MR, Maw KL, Feldman GE, Fujiwara PI, Frieden TR. 1999. The use of legal action in New York City to ensure treatment of tuberculosis. N Engl J Med 340:359–366. [PubMed]
4. Burman WJ, Cohn DL, Rietmeijer CA, Judson FN, Sbarbaro JA, Reves RR. 1997. Short-term incarceration for the management of noncompliance with tuberculosis treatment. Chest 112:57–62. [PubMed]
5. Pursnani S, Srivastava S, Ali S, Leibert E, Rogers L. 2014. Risk factors for and outcomes of detention of patients with TB in New York City: an update: 2002–2009. Chest 145:95–100. [PubMed]
6. Horsburgh CR, Moore M, Castro KG. 2004. Epidemiology of tuberculosis in the United States, p 31–45. In Rom WN, Garay SM (ed), Tuberculosis. Williams and Wilkins, Philadelphia, PA.
7. Centers for Disease Control and Prevention. 2015. Reported Tuberculosis in the United States, 2014. US Department of Health and Human Services, CDC, Atlanta, GA. https://www.cdc.gov/tb/statistics/reports/2014/pdfs/tb-surveillance-2014-report_updated.pdf
8. Institute of Medicine. 2000. Ending Neglect: the Elimination of Tuberculosis in the United States. National Academy Press, Washington, DC.
9. Salinas JL, Mindra G, Haddad MB, Pratt R, Price SF, Langer AJ. 2016. Leveling of tuberculosis incidence—United States, 2013–2015. MMWR Morb Mortal Wkly Rep 65:273–278. [PubMed]
10. Tuberculosis Along the US-Mexico Border Work Group, Centers for Disease Control and Prevention. 2001. Preventing and controlling tuberculosis along the U.S.-Mexico border. MMWR Recommend Rep 50(RR-1) :1–27.
11. Regazzi M, Carvalho AC, Villani P, Matteelli A. 2014. Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins. Clin Pharmacokinet 53:489–507. [PubMed]
12. Binkin NJ, Vernon AA, Simone PM, McCray E, Miller BI, Schieffelbein CW, Castro KG. 1999. Tuberculosis prevention and control activities in the United States: an overview of the organization of tuberculosis services. Int J Tuberc Lung Dis 3:663–674. [PubMed]
13. Marbury v Madison, 5 US 137 (1803).
14. US Constitution, article I, section 8.
15. 42 US Code section 264.
16. Code of Federal Regulations. 2017. Title 42. Public health service, department of health and human services. Subchapter F. Quarantine, inspection, licensing. Part 70. Interstate quarantine. 42 CFR 70. Fed Regist 82:6890–6978. https://www.gpo.gov/fdsys/pkg/FR-2017-01-19/pdf/2017-00615.pdf [PubMed]
17. Code of Federal Regulations. 2017. Title 42. Public health service, department of health and human services. Subchapter F. Quarantine, inspection, licensing. Part 71. Foreign quarantine. 42 CFR 71. Fed Regist 82:6890–6978. https://www.gpo.gov/fdsys/pkg/FR-2017-01-19/pdf/2017-00615.pdf [PubMed]
18. Federal Register. 2015. Criteria for requesting federal travel restrictions for public health purposes, including for viral hemorrhagic fevers. Fed Regist 80:16400–16402.
19. Centers for Disease Control and Prevention. 2008. Federal air travel restrictions for public health purposes—United States, June 2007–May 2008. MMWR Morb Mortal Wkly Rep 57:1009–1012. [PubMed]
20. World Health Organization. 2008. Tuberculosis and Air Travel: Guidelines for Prevention and Control, 3rd ed. World Health Organization, Geneva, Switzerland.
21. World Health Organization. 2005. International Health Regulations (2005), 2nd ed. World Health Organization, Geneva, Switzerland. http://www.who.int/ihr/9789241596664/en/index.html.
22. US Constitution, Tenth Amendment.
23. Jacobson v Massachusetts, 197 US 11, 1905.
24. Advisory Council for the Elimination of Tuberculosis. 1993. Tuberculosis control laws—United States, 1993. Recommendations of the Advisory Council for the Elimination of Tuberculosis (ACET). MMWR Recommend Rep 42(RR-15) :1–28. [PubMed]
25. US Constitution, First Amendment.
26. Washington v Cambra 165 F.3d 920 (Cal. 1998).
27. 42 US Code section 247b–6. National Strategy for Combating and Eliminating Tuberculosis.
28. Centers for Disease Control and Prevention. 1999. Framework for program evaluation in public health. MMWR Recommend Rep 48(RR-11) :1–40. [PubMed]
29. Hughes S, Sodt D, Young K, Jereb J, Pratt B, Navin T, Ijaz K, Khan A. 2010. Monitoring tuberculosis control programmatic activities in the United States—the National Tuberculosis Indicator Project (NTIP). MMWR Morb Mortal Wkly Rep 59:295–298.
30. Young KH, Ehman M, Reves R, Peterson Maddox BL, Khan A, Chorba TL, Jereb J. 2016. Tuberculosis contact investigations—United States, 2003–2012. MMWR Morb Mortal Wkly Rep 64:1369–1374. [PubMed]
31. Lofy KH, McElroy PD, Lake L, Cowan LS, Diem LA, Goldberg SV, Cangelosi GA, Tribble SP, Cave MD, Narita M. 2006. Outbreak of tuberculosis in a homeless population involving multiple sites of transmission. Int J Tuberc Lung Dis 10:683–689. [PubMed]
32. Saunders DL, Olive DM, Wallace SB, Lacy D, Leyba R, Kendig NE. 2001. Tuberculosis screening in the federal prison system: an opportunity to treat and prevent tuberculosis in foreign-born populations. Public Health Rep 116:210–218.
33. Barry MA, Wall C, Shirley L, Bernardo J, Schwingl P, Brigandi E, Lamb GA. 1986. Tuberculosis screening in Boston’s homeless shelters. Public Health Rep 101:487–494. [PubMed]
34. Puisis M, Feinglass J, Lidow E, Mansour M. 1996. Radiographic screening for tuberculosis in a large urban county jail. Public Health Rep 111:330–334. [PubMed]
35. Posey DL, Naughton MP, Willacy EA, Russell M, Olson CK, Godwin CM, McSpadden PS, White ZA, Comans TW, Ortega LS, Guterbock M, Weinberg MS, Cetron MS, Centers for Disease Control and Prevention. 2014. Implementation of new TB screening requirements for U.S.-bound immigrants and refugees—2007–2014. MMWR Morb Mortal Wkly Rep 63:234–236. [PubMed]
36. Centers for Disease Control and Prevention. 2009. CDC Immigration Requirements: Technical Instructions for Tuberculosis Screening and Treatment Using Cultures and Directly Observed Therapy. Centers for Disease Control and Prevention, Atlanta, GA.
37. Dara M, Gushulak BD, Posey DL, Zellweger JP, Migliori GB. 2013. The history and evolution of immigration medical screening for tuberculosis. Expert Rev Anti Infect Ther 11:137–146. [PubMed]
38. Centers for Disease Control and Prevention. 2005. Multi-drug resistant tuberculosis in Hmong refugees resettling from Thailand to the United States, 2004–2005. MMWR Morb Mortal Wkly Rep 30:741–744.
39. Maloney SA, Fielding KL, Laserson KF, Jones W, Nguyen TN, Dang QA, Nguyen HP, Nguyen AT, Duong TC, Vo TC, Seawright MF, O’Rourke T, Truong XL, Nguyen TN, Binkin N, Cetron MS. 2006. Assessing the performance of overseas tuberculosis screening programs: a study among US-bound immigrants in Vietnam. Arch Intern Med 166:234–240. [PubMed]
40. Weis SE, Moonan PK, Pogoda JM, Turk L, King B, Freeman-Thompson S, Burgess G. 2001. Tuberculosis in the foreign-born population of Tarrant County, Texas by immigration status. Am J Respir Crit Care Med 164:953–957. [PubMed]
41. Wells CD, Zuber PL, Nolan CM, Binkin NJ, Goldberg SV. 1997. Tuberculosis prevention among foreign-born persons in Seattle—King County, Washington. Am J Respir Crit Care Med 156:573–577. [PubMed]
42. Taylor Z, Nolan CM, Blumberg HM, American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. 2005. Controlling tuberculosis in the United States. Recommendations from the American Thoracic Society, CDC, and the Infectious Diseases Society of America. MMWR Recommend Rep 54(RR-12) :1–81. [PubMed]
43. Centers for Disease Control and Prevention. 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs—worldwide, 2000–2004. MMWR Morb Mortal Wkly Rep 55:301–305. [PubMed]
44. Liu Y, Posey DL, Cetron MS, Painter JA. 2015. Effect of a culture-based screening algorithm on tuberculosis incidence in immigrants and refugees bound for the United States: a population-based cross-sectional study. Ann Intern Med 162:420–428. [PubMed]
45. Centers for Disease Control and Prevention. 2016. Reported Tuberculosis in the United States, 2015. US Department of Health and Human Services, CDC, Atlanta, GA. https://www.cdc.gov/tb/statistics/reports/2015/pdfs/2015_surveillance_report_fullreport.pdf.
46. American Thoracic Society, Centers for Disease Control and Prevention, Infectious Diseases Society of America. 10 August 2016. Treatment of drug-susceptible tuberculosis. Clin Infect Dis doi:10.1093/cid/ciw376.
47. TB CARE I. 2014. International Standards for Tuberculosis Care, 3rd ed. TB CARE I, The Hague, The Netherlands.
48. Cummings KC, Mohle-Boetani J, Royce SE, Chin DP. 1998. Movement of tuberculosis patients and the failure to complete antituberculosis treatment. Am J Respir Crit Care Med 157:1249–1252. [PubMed]
49. Centers for Disease Control and Prevention. 2003. Post-detention completion of tuberculosis treatment for persons deported or released from the custody of the Immigration and Naturalization Service—United States, 2003. MMWR Morb Mortal Wkly Rep 52:438–441. [PubMed]
50. Centers for Disease Control and Prevention. 2007. Deportation of tuberculosis patients complicated by a medication shortage—Honduras, May–August 2006. MMWR Morb Mortal Wkly Rep 56:655–658. [PubMed]
51. Ferebee SH. 1970. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc 26:28–106. [PubMed]
52. Miramontes R, Hill AN, Yelk Woodruff RS, Lambert LA, Navin TR, Castro KG, LoBue PA. 2015. Tuberculosis infection in the United States: prevalence estimates from the National Health and Nutrition Examination Survey, 2011–2012. PLoS One 10:e0140881. [PubMed]
53. American Thoracic Society. 2000. Targeted tuberculin testing and treatment of latent tuberculosis infection. MMWR Recommend Rep 49(RR-6) :1–51.
54. Centers for Disease Control and Prevention. 2011. Recommendations for use of an isoniazid-rifapentine regimen with direct observation to treat latent Mycobacterium tuberculosis infection. MMWR Morb Mortal Wkly Rep 60:1650–1653. [PubMed]
55. Mazurek GH, Villarino ME, Centers for Disease Control and Prevention. 2003. Guidelines for using the QuantiFERON-TB test for diagnosing latent Mycobacterium tuberculosis infection. MMWR Recommend Rep 52(RR-2) :15–18. [PubMed]
56. Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K, IGRA Expert Committee, Centers for Disease Control and Prevention. 2010. Updated guidelines for using interferon gamma release assays to detect Mycobacterium tuberculosis infection—United States, 2010. MMWR Recommend Rep 59(RR05) :1–25. [PubMed]
57. Lobue P, Menzies D. 2010. Treatment of latent tuberculosis infection: an update. Respirology 15:603–622. [PubMed]
58. Sterling TR, Villarino ME, Borisov AS, Shang N, Gordin F, Bliven-Sizemore E, Hackman J, Hamilton CD, Menzies D, Kerrigan A, Weis SE, Weiner M, Wing D, Conde MB, Bozeman L, Horsburgh CR, Jr, Chaisson RE, TB Trials Consortium PREVENT TB Study Team. 2011. Three months of rifapentine and isoniazid for latent tuberculosis infection. N Engl J Med 365:2155–2166. [PubMed]
59. Menzies D, Dion MJ, Rabinovitch B, Mannix S, Brassard P, Schwartzman K. 2004. Treatment completion and costs of a randomized trial of rifampin for 4 months versus isoniazid for 9 months. Am J Respir Crit Care Med 170:445–449. [PubMed]
60. Shepardson D, MacKenzie WR. 2014. Update on cost-effectiveness of a 12-dose regimen for latent tuberculous infection at new rifapentine prices. Int J Tuberc Lung Dis 18:751. [PubMed]
61. Belknap R, Borisov A, Holland D, Feng P-J, Millet J-P, Martinson N, Wright A, Chen M, Cayla J, Mida JM. 2015. Adherence to once-weekly self-administered INH and rifapentine for latent TB: iAdhere (abstract 827LB). Conf Retroviruses Opportunistic Infect 2015, Seattle, WA.
62. Shinnick TM, Iademarco MF, Ridderhof JC. 2005. National plan for reliable tuberculosis laboratory services using a systems approach. Recommendations from CDC and the Association of Public Health Laboratories Task Force on Tuberculosis Laboratory Services. MMWR Recommend Rep 54(RR-6) :1–12. [PubMed]
63. APHL Steering Committee. 2009. Core TB Laboratory Services for Public Health Laboratories. Association of Public Health Laboratories, Silver Spring, MD.
64. Association of Public Health Laboratories. 2012. National TB Services Survey Report. Association of Public Health Laboratories, Silver Spring, MD.
65. Centers for Disease Control and Prevention. 2009. Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep 58:7–10. [PubMed]
66. Centers for Disease Control and Prevention. 2013. Availability of an assay for detecting Mycobacterium tuberculosis, including rifampin-resistant strains, and considerations for its use—United States, 2013. MMWR Morb Mortal Wkly Rep 62:821–827. [PubMed]
Loading

Article metrics loading...

/content/journal/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016
2017-03-03
2021-04-15

Abstract:

Because tuberculosis is caused by an infectious organism that is spread from person to person through the air, public health measures are essential to control the disease. There are three priority strategies for tuberculosis prevention and control in the United States: (i) identifying and treating persons who have tuberculosis disease; (ii) finding persons exposed to infectious tuberculosis patients, evaluating them for infection and disease, and providing subsequent treatment, if appropriate; and (iii) testing populations at high risk for latent tuberculosis infection (LTBI) and treating those persons who are infected to prevent progression to disease. These strategies for prevention and control of tuberculosis are discussed in a framework containing the following important topics: historical and epidemiological context of tuberculosis control, organization of public health tuberculosis control programs, legal basis for public health authority, conducting overall planning and development of policy, identifying persons who have clinically active tuberculosis, evaluation of immigrants, managing persons who have or who are suspected of having disease, medical consultation, interjurisdictional referrals, identifying and managing persons infected with , providing laboratory and diagnostic services, collecting and analyzing data, and providing training and education. This chapter describes the role of the health department in the context of these components. This discussion is primarily applicable to tuberculosis prevention and control programs in the United States.

Highlighted Text: Show | Hide
Loading full text...

Full text loading...

/deliver/fulltext/microbiolspec/5/2/TNMI7-0034-2016.html?itemId=/content/journal/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016&mimeType=html&fmt=ahah

Figures

Role of the Health Department in Tuberculosis Prevention and Control—Legal and Public Health Considerations
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-1,webId=/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-1,properties={foaf_givenname=Carla, foaf_name=Carla Jeffries, foaf_surname=Jeffries, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-aff1]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-2,webId=/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-2,properties={foaf_givenname=Phil, foaf_name=Phil Lobue, foaf_surname=Lobue, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-aff2]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-3,webId=/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-3,properties={foaf_givenname=Terence, foaf_name=Terence Chorba, foaf_surname=Chorba, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-aff3]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-4,webId=/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-4,properties={foaf_givenname=Beverly, foaf_name=Beverly Metchock, foaf_surname=Metchock, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-aff4]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-5,webId=/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-5,properties={foaf_givenname=Ijaz, foaf_name=Ijaz Kashef, foaf_surname=Kashef, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-aff5]]}]]
Citation: Jeffries C, Lobue P, Chorba T, Metchock B, Kashef I. 2017. Role of the health department in tuberculosis prevention and control—legal and public health considerations. microbiolspec 5(2): doi:10.1128/microbiolspec.TNMI7-0034-2016
/content/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016.fig1
FIGURE 1
Tuberculosis screening medical examination for applicants ≥2 years of age in countries with a WHO-estimated tuberculosis incidence rate of ≥20 cases per 100,000 population.
microbiolspec/5/2/TNMI7-0034-2016-fig1_thmb.gif
microbiolspec/5/2/TNMI7-0034-2016-fig1.gif
Image of FIGURE 1

Click to view

FIGURE 1

Tuberculosis screening medical examination for applicants ≥2 years of age in countries with a WHO-estimated tuberculosis incidence rate of ≥20 cases per 100,000 population.

Source: microbiolspec March 2017 vol. 5 no. 2 doi:10.1128/microbiolspec.TNMI7-0034-2016
Permissions and Reprints Request Permissions
Download as Powerpoint
/content/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016.fig2
FIGURE 2
TB regional training and medical consultation centers (TB RTMCCs).
microbiolspec/5/2/TNMI7-0034-2016-fig2_thmb.gif
microbiolspec/5/2/TNMI7-0034-2016-fig2.gif
Image of FIGURE 2

Click to view

FIGURE 2

TB regional training and medical consultation centers (TB RTMCCs).

Source: microbiolspec March 2017 vol. 5 no. 2 doi:10.1128/microbiolspec.TNMI7-0034-2016
Permissions and Reprints Request Permissions
Download as Powerpoint

Tables

Role of the Health Department in Tuberculosis Prevention and Control—Legal and Public Health Considerations
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-1,webId=/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-1,properties={foaf_givenname=Carla, foaf_name=Carla Jeffries, foaf_surname=Jeffries, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-aff1]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-2,webId=/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-2,properties={foaf_givenname=Phil, foaf_name=Phil Lobue, foaf_surname=Lobue, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-aff2]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-3,webId=/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-3,properties={foaf_givenname=Terence, foaf_name=Terence Chorba, foaf_surname=Chorba, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-aff3]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-4,webId=/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-4,properties={foaf_givenname=Beverly, foaf_name=Beverly Metchock, foaf_surname=Metchock, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-aff4]]}], com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-5,webId=/content/author/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-5,properties={foaf_givenname=Ijaz, foaf_name=Ijaz Kashef, foaf_surname=Kashef, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016-aff5]]}]]
Citation: Jeffries C, Lobue P, Chorba T, Metchock B, Kashef I. 2017. Role of the health department in tuberculosis prevention and control—legal and public health considerations. microbiolspec 5(2): doi:10.1128/microbiolspec.TNMI7-0034-2016
/content/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016.T1
TABLE 1
Selected cases involving relevant constitutional provisions
Generic image for table

Click to view

TABLE 1

Selected cases involving relevant constitutional provisions

Source: microbiolspec March 2017 vol. 5 no. 2 doi:10.1128/microbiolspec.TNMI7-0034-2016
/content/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016.T2
TABLE 2
National tuberculosis program objective categories
Generic image for table

Click to view

TABLE 2

National tuberculosis program objective categories

Source: microbiolspec March 2017 vol. 5 no. 2 doi:10.1128/microbiolspec.TNMI7-0034-2016
/content/microbiolspec/10.1128/microbiolspec.TNMI7-0034-2016.T3
TABLE 3
Possible components of a multifaceted, patient-centered treatment strategy
Generic image for table

Click to view

TABLE 3

Possible components of a multifaceted, patient-centered treatment strategy

Source: microbiolspec March 2017 vol. 5 no. 2 doi:10.1128/microbiolspec.TNMI7-0034-2016

Supplemental Material

No supplementary material available for this content.

Back to top
This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error